FDA 483 - Acino Products, LLC - July 01, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Acino Products, LLC in Hamilton, NJ, from June 15 to July 1, 2021, revealed numerous significant deficiencies in their drug manufacturing operations. The firm was cited for inadequate quality control procedures, poor facility maintenance, unqualified equipment, insufficient stability and raw material testing, and a lack of employee training. Several of these observations were repeats from prior FDA 483 inspections, indicating persistent non-compliance with cGMP regulations.
ID · 9a772c5e-1b86-435c-8d9f-356366992be3